Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor × marizomib × Clear all

Status

No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Multiple Myeloma 5 Recurrence 3 Glioblastoma 3 Lymphoma 2 Glioma 2 Brain Neoplasms 2 Solid Tumor 1 Pancreatic Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia 1 Gliosarcoma 1 Diffuse Intrinsic Pontine Glioma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 11 Injections 11 Paclitaxel 10 Docetaxel 9 Cisplatin 8 Capecitabine 8 Nivolumab 7 Fluorodeoxyglucose F18 7 Bevacizumab 7 toripalimab 6 senaparib 6 atezolizumab 6 Irinotecan 6 Fluorouracil 6 tislelizumab 5 Cyclophosphamide 5 apatinib 4 Leucovorin 4 Ipilimumab 4 Gemcitabine 4 spartalizumab 3 pertuzumab 3 olaparib 3 fludarabine 3 camrelizumab 3 Rifampin 3 Radiosurgery 3 Oxaliplatin 3 Midazolam 3 Itraconazole 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04644107 2020-11-25

Expanded Access for Marizomib

Celgene

No longer available

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡